Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas announces further approval of Flomax capsules

Astellas announces further approval of Flomax capsules

2nd October 2009

Astellas has revealed that the Food and Drug Administration (FDA) has granted an additional six months of paediatric exclusivity for Flomax (tamsulosin hydrochloride) capsules.

The treatment is designed for use in paediatric patients with neurogenic bladder conditions and met the terms of a previously signed agreement in 2006.

Results of the drug’s testing were submitted to the FDA by Boehringer Ingleheim Pharmaceuticals and the additional period attaches to the patent covering Flomax, extending its exclusivity to April 2010.

Used to treat the symptoms of benign prostatic hyperplasia, the therapy was devised by Astellas and has since been marketed in around 90 countries since its launch in 1993.

This news comes after Astellas revealed that it has opened its new Genome Medical Science Laboratory at the University of Tokyo, which aims to work on the development of new cancer treatments.

The firm will contribute 15 million yen (99,870 pounds) to the unit annually for a duration of five years.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.